Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors

被引：0
|
作者：
Lin, C-C. [1 ]
Schneider, R. [2 ]
Gutierrez, M. [3 ]
Shen, L. [4 ]
Chung, K. [5 ]
Doroshow, D. B. [6 ]
Gao, B. [7 ,8 ]
Millward, M. [9 ]
Hsieh, C-Y. [10 ]
Xu, C. [10 ]
Cai, S. X. [10 ]
Tian, Y. E. [10 ]
Liu, L. [10 ]
Shen, C. [10 ]
Tan, Y. [10 ]
He, Y. [10 ]
Zhang, C. [10 ]
Li, L. [11 ]
Ma, M. [10 ]
Xu, L. [10 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[2] Mary Crowley Canc Res, Dept Med Oncol, Dallas, TX USA
[3] Hackensack Univ, Dept Med Oncol, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[4] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China
[5] Prisma Hlth Syst Upstate, Clin Res, Inst Translat Oncol Res, Greenville, SC USA
[6] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, New York, NY 10029 USA
[7] Blacktown Hosp, Haematol & Canc Care Ctr, Blacktown, NSW, Australia
[8] Univ Sydney, Blacktown, NSW, Australia
[9] Linear Clin Res, Oncol, Perth, WA, Australia
[10] IMPACT Therapeut Inc Shanghai, Clin Dev, Shanghai, Peoples R China
[11] IQVIA RDS Shanghai Co Ltd, Beijing Branch, Med, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.699
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
632P
引用
收藏
页码：S503 / S504
页数：2
相关论文
共 50 条
  • [21] First-in-human Phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors.
    Hollebecque, Antoine
    Soria, Jean-Charles
    Bahleda, Ratislav
    Lopez-Busto, Natividad
    Jacquet-Bescond, Anne
    Burbridge, Mike F.
    Valerie, Cattan
    Pauly, Jeanne
    Herranz, Maria
    Azaro, Analia
    Depil, Stephane
    Rodon, Jordi
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [22] A Phase I dose-escalation study of ATR inhibitor monotherapy with AZD6738 in advanced solid tumors (PATRIOT Part A)
    Dillon, Magnus T.
    Espinasse, Aude
    Ellis, Sally
    Mohammed, Kabir
    Grove, Lorna G.
    McLellan, Lyndall
    Smith, Simon A.
    Ross, Graham
    Adeleke, Sola
    Woo, Kin
    Josephides, Eleni
    Spicer, James F.
    Forster, Martin D.
    Harrington, Kevin J.
    CANCER RESEARCH, 2017, 77
  • [23] A first-in-human (FIH) phase I study of SAR12544, a novel selective MET kinase inhibitor, in patients (pts) with advanced solid tumors: Dose escalation results
    Angevin, Eric
    Spitaleri, Gianluca
    Hollebecque, Antoine
    De Pas, Tommaso
    Soria, Jean-Charles
    Harnols, Marzia
    Mazuir, Florent
    Assadourlan, Sylvie
    De Marinis, Filippo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part
    Doi, Toshihiko
    Matsubara, Nobuaki
    Naito, Yoichi
    Kuboki, Yasutoshi
    Harano, Kenichi
    Ono, Makiko
    Urasaki, Tetsuya
    Ohmoto, Akihiro
    Kawanai, Tsubasa
    Hisai, Takashi
    Ikezawa, Hiroki
    Shiba, Sari
    Ito, Ken
    Semba, Taro
    Asano, Osamu
    Takahashi, Shunji
    CANCER, 2023, 129 (15) : 2348 - 2359
  • [25] First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
    Sessa, Cristiana
    Shapiro, Geoffrey I.
    Bhalla, Kapil N.
    Britten, Carolyn
    Jacks, Karen S.
    Mita, Monica
    Papadimitrakopoulou, Vali
    Pluard, Tim
    Samuel, Thomas A.
    Akimov, Mikhail
    Quadt, Cornelia
    Fernandez-Ibarra, Cristina
    Lu, Hong
    Bailey, Stuart
    Chica, Sandra
    Banerji, Udai
    CLINICAL CANCER RESEARCH, 2013, 19 (13) : 3671 - 3680
  • [26] A phase I, first-in-human, dose-escalation and dose expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
    Piha-Paul, Sarina Anne
    Wan, Qunfang
    Xiong, Wendy
    Peng, Peng
    Yang, Xiaoju
    Wu, Henry
    Ngo, Brenda
    Wu, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] First-in-human dose-escalation study of basroparib (STP1002) in patients with advanced-stage solid tumors
    Lieu, C.
    Lenz, H. J.
    Kim, K. P.
    Sung, M. J.
    Kim, U-I.
    Meng, X.
    Benson, A. B., III
    ANNALS OF ONCOLOGY, 2024, 35 : S504 - S504
  • [28] Results of a completed first-in-human phase Ib dose-escalation study of oral CBL0137 in patients with advanced solid tumors.
    Fedyanin, Mikhail
    Tryakin, Alexey
    Lisyanskaya, Alla Sergeevna
    Solovyeva, Ekaterina
    Fadeeva, Natalia
    Gladkov, Oleg
    Moiseyenko, Vladimir
    Cheporov, Sergey, V
    Shpigotskaya, Polina
    Purmal, Andrei
    Miller, Langdon L.
    Leonov, Andrey
    Zakurdaeva, Kristina
    Gurova, Katerina
    Gudkov, Andrei
    Tjulandin, Sergei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors
    Babu, S.
    Kondo, S.
    Ammakkanavar, N.
    Spira, A. I.
    Perets, R.
    Doi, T.
    Bar, J.
    Vandross, A.
    Sommerhalder, D.
    Nikolic, V.
    Tribouley, C.
    Atluri, H.
    Hong, J.
    Paustian, A.
    Leibman, R.
    Powderly, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S647 - S648
  • [30] Phase 1 first-in-human study of anti-ILT3 mAb MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors: Dose escalation results
    Gutierrez, Martin
    Spreafico, Anna
    Wang, Ding
    Golan, Talia
    Renouf, Daniel
    Voskoboynik, Mark
    Chatterjee, Manash Shankar
    Kapadia, Kishan J.
    Liu, Qi
    Kovvali, Gopala
    Suttner, Leah
    Pang, Ling
    Chen, Mei
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345